Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.

@article{Cicinnati2007ClinicalTS,
  title={Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.},
  author={Vito Rosario Cicinnati and Z Yu and Christian Klein and Georgios C Sotiropoulos and Fuat Hakan Saner and Massimo Mal{\'a}go and Andrea Frilling and Guido G H Gerken and Christoph Erich Broelsch and Susanne Beckebaum},
  journal={Alimentary pharmacology & therapeutics},
  year={2007},
  volume={26 9},
  pages={1195-208}
}
BACKGROUND Calcineurin inhibitor (CNI)-related nephrotoxicity significantly contributes to chronic renal failure after liver transplantation. METHODS In this prospective study, liver transplantation patients with renal dysfunction were randomized either to receive mycophenolate mofetil (MMF) followed by stepwise reduction of CNI with defined minimal CNI-trough levels (MMF group), or to continue their maintenance CNI dose (control group). Immune monitoring was performed in a subgroup of the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…